Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-P3 PET/CT Imaging in Prostate
Sponsor: Peking University First Hospital
Summary
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Official title: A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Prostate
Key Details
Gender
MALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-05-29
Completion Date
2025-07-31
Last Updated
2024-11-07
Healthy Volunteers
Yes
Conditions
Interventions
[68Ga]P3
68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Locations (1)
Peking University First Hospital
Beijing, Beijing Municipality, China